trending Market Intelligence /marketintelligence/en/news-insights/trending/tuvaB_rDOXDvG2ObvwaLQQ2 content esgSubNav
In This List

Endo unit begins distribution of generic version of Merck's Zetia

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Endo unit begins distribution of generic version of Merck's Zetia

Endo International PLC said the company's U.S.-based unit Par Pharmaceutical began shipping ezetimibe tablets, a generic version of Merck's cholesterol-lowering drug, Zetia.

Ezetimibe lowers low-density lipoprotein in patients with elevated blood cholesterol levels.

Par Pharmaceutical holds a licensing agreement with Glenmark Pharmaceuticals Inc. USA, through which Par is entitled to generic marketing exclusivity based on Glenmark's first-to-file abbreviated new drug application status.

According to IMS Health, U.S. sales of Zetia reached approximately $2.61 billion for the 12 months ended Sept. 30.